Cyclin-Dependent Kinase Degraders via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors face challenges in achieving high systemic drug concentrations, leading to ineffective treatment of diseases associated with deregulated cyclin-dependent kinases like CDK8 and CDK19, particularly in cancers.
Innovation Solution
Development of bifunctional compounds that recruit CDK8 and/or CDK19 to E3 ubiquitin ligases for targeted degradation, utilizing a Targeting Ligand to bind to CDK8 and/or CDK19, a Linker to covalently bind to the Degron, and the Degron to bind to an E3 ubiquitin ligase like cereblon, facilitating proteasomal degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CDK inhibitors are used, then CDK activity is inhibited, but systemic drug concentration remains insufficient for effective treatment
Solution Approach 1:
The patent extracts the target protein (CDK8 or CDK19) from the cell and removes it through proteasomal degradation. By using bifunctional compounds that recruit the target to E3 ubiquitin ligases, the invention selectively extracts and eliminates the problematic protein rather than merely inhibiting its activity, thereby achieving effective treatment with lower drug concentrations.
Solution Approach 2:
The patent converts the harmful presence of CDK8/CDK19 into a beneficial process by exploiting the cell's own ubiquitin-proteasome system. The bifunctional compounds redirect the target protein to E3 ubiquitin ligases, transforming the protein's presence from harmful to the mechanism of its own degradation, thereby achieving effective inhibition through protein removal rather than traditional inhibition.
2Reliability
If bifunctional compounds are designed to recruit CDK8/CDK19 to E3 ubiquitin ligases, then targeted degradation is achieved, but compound structure and mechanism become more complex
Solution Approach 1:
The patent segments the bifunctional compound into two distinct functional moieties: a first moiety that binds to the target protein (CDK8 or CDK19) and a second moiety that binds to the E3 ubiquitin ligase. This segmentation allows each part to be optimized independently for its specific binding function, achieving reliable targeted degradation while maintaining manageable structural complexity through modular design.
Solution Approach 2:
The patent introduces an intermediary mechanism using E3 ubiquitin ligases as mediators between the target protein and the proteasome. The bifunctional compound facilitates this intermediary process by simultaneously binding to both the target and the E3 ligase, thereby enabling targeted degradation through a controlled intermediate step rather than direct protein-protein interaction.
3Productivity
If conventional inhibitors are used, then treatment is administered, but safety and efficacy are insufficient for cancer treatment
Solution Approach 1:
The patent applies local quality by creating specificity in the binding interactions. The first moiety is designed with high affinity for the target protein (CDK8 or CDK19), and the second moiety is designed with high affinity for the E3 ubiquitin ligase. This localized specificity ensures that the compound acts only on the intended target through the intended mechanism, improving treatment efficacy while reducing off-target effects and enhancing safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds effectively modulate CDK8 and/or CDK19 levels, providing therapeutic agents with improved efficacy and safety for treating diseases such as cancer by specifically degrading these kinases.
Implementation Method 1
Ubiquitin-Proteasome Pathway (UPP) is a critical pathway that regulates proteins and degrades misfolded or abnormal proteins. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases.
Implementation Method 2
Bifunctional compounds composed of a target protein-binding moiety and an E3 ubiquitin ligase-binding moiety have been shown to induce proteasome-mediated degradation of selected proteins.
Data Source
AI summary
The present application provides bifunctional compounds of Formula (Ia):Targeting Ligandor an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or more of cyclin-dependent kinase 8 (CDK8) and cyclin-dependent kinase 19 (CDK19). The present application also relates to methods for the targeted degradation of CDK8 and/or CDK19 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 and/or CDK19 which can be utilized in the treatment of disorders modulated by CDK8 and/or CDK19.